Evolus 

€14.8
27
-€0.3-1.99% 今天

統計

當日最高
14.8
當日最低
14.8
52週最高
-
52週最低
-
成交量
0
平均成交量
-
市值
994.77M
市盈率
-
股息收益率
-
股息
-

即將到來

收益

5Nov預期
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一個
-0.32
-0.23
-0.13
-0.04
預期每股收益
-0.1237
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 EVL.F 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

關於

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Show more...
首席執行官
Mr. David Moatazedi
員工
304
國家
US
ISIN
US30052C1071
WKN
000A2JDYX

上市公司